ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "proteomics"

  • Abstract Number: 1176 • ACR Convergence 2022

    Immunoglobulins G from Systemic Sclerosis Patients May Alter the Secretome of Dermal Fibroblasts

    Aurélien Chepy1, Marie Duhamel2, Solange Vivier3, lucile Guilbert3, Eric Hachulla4, Sylvain Dubucquoi3, David Launay3, Michel Salzet2 and Vincent Sobanski3, 1CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, 2Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, 3Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, 4University of Lille, LILLE, France

    Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc).Recently, it has been shown that immunoglobulins G (IgG) from SSc promoted a proinflammatory and profibrotic phenotype…
  • Abstract Number: 0386 • ACR Convergence 2022

    Quantitative Proteomic Screening Uncovers Diagnostic and Monitoring Serum Biomarkers of Ankylosing Spondylitis

    Mark Hwang1, Jessica Castillo2, kamala Vanarsa2, Jim Zheng3, Shervin Assassi4, Chandra Mohan2 and John Reveille5, 1McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, 2University of Houston, Houston, TX, 3UTHealth School of Bioinformatics, Houston, TX, 4McGovern Medical School, University of Texas, Houston, TX, 5University of Texas McGovern Medical School, Houston, TX

    Background/Purpose: We sought to discover novel serum biomarkers of ankylosing spondylitis (AS) for diagnosis and monitoring disease activity. Methods: We used biologic-treatment naïve AS and…
  • Abstract Number: 1537 • ACR Convergence 2022

    Proteomic Profiling of Plasma Microvesicles Isolated from Patients with Systemic Sclerosis

    Line Iversen1, Ole Østergaard2, Tina Friis3, susanne Ullman4, Søren Jacobsen5 and Jesper Olsen2, 1Department of Dermatology, Odense University Hospital., Odense, Denmark, 2Novo Nordisk Foundation Center for Protein Research, Copenhagen University, Copenhagen, Denmark, 3Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark, 4Department of Dermatology, Bispebjerg, Copenhagen University Hospitals, Copenhagen, Denmark, 5Department of Rheumatology, Rigshospitalet, Copenhagen University Hospitals, Copenhagen, Denmark

    Background/Purpose: In the current work, we used a mass spectrometry based proteomics workflow to analyze isolated plasma microvesicles from systemic sclerosis (SSc) patients and from…
  • Abstract Number: 0471 • ACR Convergence 2022

    Serum Proteomics in Giant Cell Arteritis: Findings of the Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab Trial (The GUSTO Trial)

    Lisa Christ1, Andrea Gloor2, Florian Kollert1, Timo Gaber3, Frank Buttgereit3, Stephan Reichenbach4 and Peter Villiger5, 1Department of Rheumatology and Immunology, University of Bern, Inselspital, Bern, Switzerland, 2Department of Internal Medicine, University of Bern, Inselspital, Bern, Switzerland, 3Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, 4University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland, 5Medical Center Monbijou, Rheumatology and Immunology, Bern, Switzerland

    Background/Purpose: Measuring disease activity in patients with giant cell arteritis (GCA) remains challenging since appropriate biomarkers are missing, particularly, if tocilizumab (TCZ) is prescribed which…
  • Abstract Number: 1632 • ACR Convergence 2022

    Novel Autoantibodies Identify Sjögren’s Disease in Patients Lacking Serum IgG Specific for Ro/SS-A and La/SS-B

    Sherri Longobardi1, Charmaine Lopez-Davis1, Bhuwan Khatri1, Constantin Georgescu1, Christina Lawrence1, Astrid Rasmussen1, Lida Radfar2, R. Hal Scofield2, Robert C. Axtell1, Gabriel Pardo1, Jonathan Wren1, Kristi A Koelsch1, Joel Guthridge1, Judith James1, Christopher Lessard1 and A. Darise Farris1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Classification of Sjögren's disease (SjD) requires either Ro/SS-A autoantibodies or minor salivary gland biopsy positive for focal lymphocytic infiltrates. Up to 40% of SjD…
  • Abstract Number: 0536 • ACR Convergence 2022

    Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria

    Andrea Fava1, Laurence S Magder2, Daniel W. Goldman3, Jill Buyon4, Betty Diamond5, Joel Guthridge6, William Apruzzese7, Derek Fine1, Jose Monroy-Trujillo1, Mohamed G. Atta1, Peter Izmirly4, H Michael Belmont8, Anne Davidson5, Maria Dall'Era9, Deepak Rao7, Arnon Arazi10, Nir Hacohen11, Soumya Raychaudhuri7, the Accelerating Medicines Partnership (AMP) RA/SLE12 and Michelle Petri3, 1Johns Hopkins University, Baltimore, MD, 2University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 4NYU Grossman School of Medicine, New York, NY, 5Feinstein Institutes for Medical Research, Manhasset, NY, 6Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Brigham and Women's Hospital, Boston, MA, 8NYU School of Medicine, New York, NY, 9University of California, San Francisco, San Francisco, 10Feinstein Institutes for Medical Research, Melrose, MA, 11Broad Institute, Cambridge, MA, 12Multiple Insitutions

    Background/Purpose: A decline of urine protein-to-creatinine ratio (UPCR) to < 0.5 is associated with better long-term preservation of kidney function in lupus nephritis (LN). UPCR…
  • Abstract Number: 1962 • ACR Convergence 2022

    Idiopathic Pulmonary Fibrosis Molecular Profile Correlates with Stage of Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Daniel Kass1, Mehdi Nouraie1, Yingze Zhang1, Bryant England2, Ted Mikuls3, Gail Kerr4, Andreas Reimold5, Kevin Gibson1, Marilyn Glassberg6, Paul Dellaripa7, Tracy Doyle7, Chester Oddis8 and Dana Ascherman8, 1University of Pittsburgh School of Medicine, Pittsburgh, PA, 2University of Nebraska Medical Center, Omaha, NE, 3Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 5North Texas Veterans Administration Health Care System, Dallas, TX, 6Loyola University Chicago Stritch School of Medicine, Chicago, IL, 7Brigham and Women's Hospital, Boston, MA, 8University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Previous studies have demonstrated clinical, epidemiologic, histopathologic, and genetic overlap between advanced rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and Idiopathic Pulmonary Fibrosis (IPF). Corresponding…
  • Abstract Number: 0611 • ACR Convergence 2022

    Proteomics Reveals Dysregulated Molecular Mechanisms of Cell Death in Neutrophils in Rheumatoid Arthritis

    Jennifer Amsler1, Constance Beaudouin2, Morgane LeGall3, Géraldine Falgarone4, François Rannou5, Léa Tourneur3 and Véronique Witko-Sarsat3, 1Institute Cochin, Schoenenwerd, Switzerland, 2Hôpital Privé de Provence, Aix-en-Provence, France, 3Institute Cochin, Paris, France, 4Hôpital Avicenne, Paris, France, 5Hôpital Cochin, Paris, France

    Background/Purpose: Favoring apoptosis of neutrophils infiltrating the joints of patients suffering from rheumatoid arthritis (RA) and perpetuating inflammation has recently been discussed as an alternative…
  • Abstract Number: 2135 • ACR Convergence 2022

    Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis

    James C Waddington1, Ruoyi Zhou1, Orla Coleman1, Bruna Wundervald2, Andrew Parnell3, Vinod Chandran4, Lara Fallon5, Douglass Chapman6, Remy Pollock7, Shibing Deng8, Oliver FitzGerald9, Stephen R Pennington10 and Philip J Mease11, 1Atturos, Dublin, Ireland, 2Atturos/Hamilton Institute, Maynooth University, Dublin, Ireland, 3Hamilton Institute, Maynooth University, Kildare, Ireland, 4Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 5Pfizer Inc, Montréal, QC, Canada, 6Pfizer Inc, New York, NY, 7Pfizer Canada ULC, Kirkland QC, Canada, 8Pfizer Inc, Waterford, MI, 9Conway Institute, University College Dublin, Dublin, Ireland, 10Atturos/Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, 11Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA.1,2 Using two mass spectrometry (MS)-based proteomic approaches (targeted multiple reaction monitoring [MRM]…
  • Abstract Number: 0616 • ACR Convergence 2022

    Serum Proteomic Networks Associate with Pre-clinical Rheumatoid Arthritis Autoantibodies and Longitudinal Outcomes

    Liam O'Neil1, XIAOBO MENG1, Caitin McFadyen1, Marvin Fritzler2 and Hani El-Gabalawy1, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Calgary, Calgary, AB, Canada

    Background/Purpose: The detection of anti-citrullinated protein antibodies (ACPA) is associated with increased risk for development of future Rheumatoid Arthritis (RA). The biological events that underpin…
  • Abstract Number: 0650 • ACR Convergence 2022

    The Association of Urinary C9 to CD59 Ratio with Tubulointerstitial Fibrosis in Lupus Nephritis

    Shudan Wang1, Masako Suzuki2, Daming Shao3, Muhammad Hamza Bukhari4, Brianna Lally5, Michael Belmont6, Jennifer Aguilan2, Simone Sidoli2, Anna Broder7 and J. Michelle Kahlenberg8, 1Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, 2Albert Einstein College of Medicine, Bronx, NY, 3Albert Einstein College of Medicine/Jacobi Medical Center, Bronx, NY, 4Norwalk Hospital/Yale University, Norkwalk, VA, 5University of Wisconsin Hospitals and Clinics, Madison, WI, 6NYU Grossman School of Medicine, New York, NY, 7Hackensack University Medical Center, Hackensack, NJ, 8University of Michigan, Ann Arbor, MI

    Background/Purpose: Animal and human studies suggest that terminal complement activation has a pathogenic role in tubulointerstitial fibrosis, which is a strong predictor of irreversible kidney…
  • Abstract Number: 0531 • ACR Convergence 2021

    Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics

    Asmaa AbuMaziad1, Abhimanyu Amarnani2 and Ram Singh3, 1University of California Los Angeles, Los Angeles, CA, 2Los Angeles County + University of Southern California, Los Angeles, CA, 3University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Lupus nephritis (LN) causes substantial morbidity and mortality. LN is histopathologically divided into six classes, which currently serves as the basis for making treatment…
  • Abstract Number: 0546 • ACR Convergence 2021

    Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis

    Kristina Clark1, Eszter Csomor2, Corrado Campochiaro3, Adam Taylor4, Yee Voan Teo2, Katherine Nevin2, Mary Morse2, Voon Ong5, Emma Derrett-Smith6, Nicolas Wisniacki2, Shaun Flint2 and Christopher Denton7, 1University College London, London, United Kingdom, 2GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, 3Royal Free Hospital London, London, United Kingdom, 4GlaxoSmithKline, London, United Kingdom, 5University College London Medical School Royal Free Campus, London, United Kingdom, 6University College London Division of Medicine, London, United Kingdom, 7University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Suction blister fluid provides a unique opportunity to analyse the dermal microenvironment of SSc. We report an integrated analysis of proteomic data from dermal…
  • Abstract Number: 0693 • ACR Convergence 2021

    Discovery of Antigen Specific CD4+ T Cells in Anti-HMGCR-positive Immune Mediated Necrotizing Myopathy

    Eleni Tiniakou1, Andrew Mammen2 and Erika Darrah1, 1Johns Hopkins University, Baltimore, MD, 2National Institutes of Health, Bethesda, MD

    Background/Purpose: Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR)-positive immune mediated necrotizing myopathy (anti-HMGCR+ IMNM) is a unique myopathy characterized by IgG autoantibodies against HMGCR and a strong…
  • Abstract Number: 1240 • ACR Convergence 2021

    Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs

    Fang Cai1, Thierry Sornasse2, Feng Hong3, Heidi Camp4, Koji Kato5 and Iain McInnes6, 1AbbVie, Redwood City, CA, 2AbbVie Inc, Redwood City, CA, 3AbbVie, Worcester, MA, 4AbbVie Inc., North Chicago, IL, 5AbbVie Inc, Shinagawa- Ku, Japan, 6University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom

    Background/Purpose: In patients with active rheumatoid arthritis (RA) refractory to biologic DMARDs (bDMARD-IR), a phase 3, double-blind and active-controlled study (SELECT-CHOICE) demonstrated that upadacitinib (UPA)…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology